My Portfolio
+
LINK YOUR PORTFOLIO

HUTCHMED (China) Ltd 13-HK:Hong Kong Stock Exchange

*Data is delayed | Exchange | HKD
Last | 1:48 PM CTT
17.93quote price arrow down-0.25 (-1.38%)
Volume
1,454,576
52 week range
17.71 - 30.75
Loading...
  • Open18.18
  • Day High18.25
  • Day Low17.82
  • Prev Close18.18
  • 52 Week High30.75
  • 52 Week High Date07/29/25
  • 52 Week Low17.71
  • 52 Week Low Date05/28/26

Latest On HUTCHMED (China) Ltd

 

Key Stats

  • Market Cap15.641B
  • Shares Out872.34M
  • 10 Day Average Volume4.85M
  • Dividend-
  • Dividend Yield-
  • Beta1.23

Latest On HUTCHMED (China) Ltd

 

KEY STATS

  • Open18.18
  • Day High18.25
  • Day Low17.82
  • Prev Close18.18
  • 52 Week High30.75
  • 52 Week High Date07/29/25
  • 52 Week Low17.71
  • 52 Week Low Date05/28/26
  • Market Cap15.641B
  • Shares Out872.34M
  • 10 Day Average Volume4.85M
  • Dividend-
  • Dividend Yield-
  • Beta1.23

RATIOS/PROFITABILITY

  • EPS (TTM)4.15
  • P/E (TTM)4.32
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-202.581M
  • ROE (TTM)45.74%
  • Revenue (TTM)4.298B
  • Gross Margin (TTM)38.68%
  • Net Margin (TTM)83.45%
  • Debt To Equity (MRQ)7.91%

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Profile

MORE
HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery...
Dan Eldar Ph.D.
Non-Executive Chairman of the Board
Chig Fung Cheng
Acting Chief Executive Officer, Chief Financial Officer, Executive Director
Charles Nixon
Group General Counsel
Address
48Th Floor, Cheung Kong Center
2 Queen's Road Central
Hong Kong